Cargando…
Identification of celastrol as a novel HIV-1 latency reversal agent by an image-based screen
Although current antiretroviral therapies (ART) are successful in controlling HIV-1 infection, a stable viral reservoir reactivates when ART is discontinued. Consequently, there is a major research effort to develop approaches to disrupt the latent viral reservoir and enhance the immune system’s abi...
Autores principales: | Liu, Hongbing, Hu, Pei-Wen, Dubrulle, Julien, Stossi, Fabio, Nikolai, Bryan C., Mancini, Michael A., Rice, Andrew P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084242/ https://www.ncbi.nlm.nih.gov/pubmed/33914760 http://dx.doi.org/10.1371/journal.pone.0244771 |
Ejemplares similares
-
NSC95397 is a Novel HIV Latency Reversing Agent
por: Nichols Doyle, Randilea, et al.
Publicado: (2023) -
Epigenetic Regulation of HIV-1 Sense and Antisense Transcription in Response to Latency-Reversing Agents
por: Li, Rui, et al.
Publicado: (2023) -
Identification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products
por: Richard, Khumoekae, et al.
Publicado: (2018) -
Systematic identification of Celastrol-binding proteins reveals that Shoc2 is inhibited by Celastrol
por: Xiao-pei, Huang, et al.
Publicado: (2018) -
HIV-1 Latency and Latency Reversal: Does Subtype Matter?
por: Sarabia, Indra, et al.
Publicado: (2019)